FDA approves Fayuvi, first treatment for Sanfilippo syndrome type A
The US Food and Drug Administration on September 17, 2026, approved Fayuvi (rebisufligene etisparvovec-hopf), a gene therapy from Ultragenyx, for pediatric patients with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. It is the first FDA-approved treatment for the disease, according to CGTLive and Contemporary Pediatrics.
"The approval of Fayuvi marks a historic moment for children and families living with MPS IIIA," FDA Acting Commissioner Kyle Diamantas said, as quoted by Contemporary Pediatrics.


